There are likely very complex relationships also occurring between various Cannabinoids in Cannabis that may lead to certain medical efficacy. That is important to remember when considering the consumption of products that contain Cannabinoids. There is an attractiveness to isolating a specific chemical, researching it, patenting synthetic derivatives, and marketing specific drugs. That said, the relationships are complex, will likely take years to understand, and many patients I’ve met appear to find the most medical benefit from a diverse group of Cannabinoids whose interactions are not particularly well understand, but the results are hard to argue with.
Having 1 organic certification is hard enough. BioBloom possesses 3: the Austrian, Swiss and Hungarian Bio certificate and the British Biodynamic Association one, making it the only Cannabidiol product available in the UK with a triple organic certification. This means that from the moment it was planted in the organic soils of an Austro-Hungarian riverbed to the moment it reaches the bottle, the entire process is supervised and tested certified organic. No machines are allowed in the hemp farms and the entire process of harvesting and drying the cannabis plants is done by hand. This is a remarkable product with a very strong taste (perhaps the strongest of all oils we’ve tried), which in our eyes means it is full of goodness. Visit the BioBloom collection.
Success stories like Oliver’s are everywhere, but there’s not a lot of data to back up those results. That’s because CBD comes from cannabis and, like nearly all other parts of the plant, is categorized by the Drug Enforcement Agency (DEA) as a Schedule 1 drug—the most restrictive classification. (Others on that list: heroin, Ecstasy, and peyote.) This classification, which cannabis advocates have tried for years to change, keeps cannabis-derived products, including CBD, from being properly studied in the U.S.
Studies have demonstrated that CBD has a low affinity for the CB1 receptors, but even at low concentrations, CBD decreases G-protein activity (3). CB1 receptors are expressed on many glutamatergic synapses that have been implicated in seizure threshold modulation. CBD may act at CB1 receptors to inhibit glutamate release (4). Studies have shown changes in the expression of CB1 receptors during epileptogenesis and after recurrent seizures (5). CB1 receptor expression is upregulated at GABAergic synapses and shown to be downregulated at glutamatergic synapses in epilepsy, contributing to lowering seizure thresholds.
High blood pressure is a globally ubiquitous issue. This study explores the connection between CBD and a reduction in blood pressure. It is particularly unique as it is noted that “there are no dedicated studies in humans to date, to our knowledge, looking at the effect of CBD on either resting cardiovascular measurement or on the responses to stress, with continuous monitoring of CV parameters.”
Cannabidiol is the major nonpsychoactive component of Cannabis sativa. Over the centuries, a number of medicinal preparations derived from C. sativa have been employed for a variety of disorders, including gout, rheumatism, malaria, pain, and fever. These preparations were widely employed as analgesics by Western medical practitioners in the 19th century (1). More recently, there is clinical evidence suggesting efficacy in HIV-associated neuropathic pain, as well as spasms associated with multiple sclerosis (1).

Over the past few years, increasing public and political pressure has supported legalization of medical marijuana. One of the main thrusts in this effort has related to the treatment of refractory epilepsy—especially in children with Dravet syndrome—using cannabidiol (CBD). Despite initiatives in numerous states to at least legalize possession of CBD oil for treating epilepsy, little published evidence is available to prove or disprove the efficacy and safety of CBD in patients with epilepsy. This review highlights some of the basic science theory behind the use of CBD, summarizes published data on clinical use of CBD for epilepsy, and highlights issues related to the use of currently available CBD products.
Cannabidiol Life of allcbdoilbenefits.com pledges to respect the FDA laws and any/all legal requirements for medical information confidentiality as well as all personal information, including identity, and this will apply to the country and state of the site visitor’s location. Visitors of this site must agree to the terms of our disclaimer & privacy policy or they should not use allcbdoilbenefits.com at all and should kindly leave immediately.
×